Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glaucoma Start-Ups Reach Critical Mass

This article was originally published in Start Up

Executive Summary

Having validated high intraocular pressure as a certain target for intervention, the Ocular Hypertension Treatment Study spurred on a new wave of innovation in medical devices for glaucoma. Numerous start-ups formed five or six years ago are now beginning to run their devices through clinical trials. Indeed, the field seems to have gained a critical mass of attention. Start-Up has identified more than a dozen emerging device companies treating glaucoma, and the disease remains a target for development programs and acquisitions on the pharmaceutical side as well.
Advertisement

Related Content

In Glaucoma, Devices Go Eye-to-Eye with Drugs
Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q2 2009
Start-Up Previews (07/2008)
Transcend Medical Inc.
Sensimed AG
Novartis' New Kind of Pharma Deal
Happy Return: QLT Bets Big on ForSight Plug
Device Companies Set Their Sights on Glaucoma
An Early Peek at Glaucoma Devices
From The Foundry, an Incubator Focused on Ophthalmology

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

MT037566

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel